WINNIPEG, Dec. 18, 2018 /CNW/ - Waverley Pharma Inc.
("Waverley Pharma" or the "Company") (TSXV:WAVE), an emerging
Canadian pharmaceutical company, is pleased to announce that its
wholly-owned subsidiary, Waverley Pharma Europe Limited ("WPEL"),
has entered into a storage and distribution agreement with
Mawdsley-Brooks & Co. Ltd. ("Mawdsleys") to distribute various
strengths of capecitabine and temololomide on WPEL's behalf to
hospitals in the United Kingdom
(UK) under binding contracts that WPEL has secured with the UK
National Health Service. These two generic oncology products
were originally developed by Reliance Life Sciences Private Limited
(RLS), and the contracts with the UK National Health Service for
the supply of these products were previously transferred to
WPEL.
Mawdsleys has begun to distribute the oncology products to UK
hospitals and Waverley Pharma is also pleased to announce that the
first sales of both capecitabine and temololomide have been
recorded.
"We are excited to achieve initial sales of our first two
generic products and develop the infrastructure and relationships
for a successful launch of WAV-101 and WAV-102, once they are
approved in the European Union," stated the Company's President and
CEO, Dr. Theron (Ted) Odlaug.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on
the development and commercialization of effective and affordable
cancer therapeutics in the EU and North American market. The
Company has two lead products at the regulatory filing stage, and
is currently evaluating other products, in different stages of
development. Waverley Pharma is committed to providing patients
with affordable prescription medicines that lower healthcare costs
and provide a better quality of life. For more information on
Waverley Pharma please visit www.waverleypharma.com.
About Mawdsleys
Founded in 1825, Mawdsleys is a privately-owned pharmaceutical
services company based in the UK with operations in Brazil and Israel. We deliver a wide range of services to
both the pharmaceutical industry and healthcare sector through our
main business areas which include: Named Patient Medicines
(delivering global named patient programmes), Product Licensing and
Market Access (In the EU, LATAM and Middle East regions), UK Wholesale (largest
independent wholesaler to UK hospitals), UK Pre-wholesale (3PL and
4PL services in the UK), LUTO (healthcare communications) and
Positive Solutions (pharmacy IT systems). For more information
please visit www.mawdsleys.co.uk
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements
contained in this press release that are not statements of
historical fact, including, without limitation, statements
containing the words "believes", "may", "plans", "will",
"estimates", "continues", "anticipates", "intends", "expects" and
similar expressions, may constitute "forward-looking information"
within the meaning of applicable Canadian and U.S. federal
securities laws (such forward-looking information and
forward-looking statements are hereinafter collectively referred to
as "forward-looking statements"). Forward-looking statements,
include the receipt of binding contracts with the UK National
Health Service, the eventual launch of WAV-101 and 102 in the
European Union, and other regulatory filings, estimates,
analysis and opinions of management of the Company made in light of
its experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances.
Inherent in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's potential product revenues, stage of
development, additional capital requirements, risks associated with
the completion and timing of clinical trials and obtaining
regulatory approval to market the Company's products, the ability
to protect its intellectual property, dependence upon collaborative
partners, changes in government regulation or regulatory approval
processes, and rapid technological change in the industry. Such
statements are based on a number of assumptions which may prove to
be incorrect, including, but not limited to, assumptions about:
general business and economic conditions; the impact of changes in
Canadian-US dollar and other foreign exchange rates on the
Company's revenues, costs and results; the timing of the receipt of
regulatory and governmental approvals for the Company's research
and development projects; the availability of financing for the
Company's commercial operations and/or research and development
projects, or the availability of financing on reasonable terms; the
uncertainties associated with the acceptance and demand for new
products and market competition. The foregoing list of important
factors and assumptions is not exhaustive. The Company undertakes
no obligation to update publicly or otherwise revise any
forward-looking statements or the foregoing list of factors, other
than as may be required by applicable legislation. Additional
discussion regarding the risks and uncertainties relating to the
Company and its business can be found in the Company's other
filings with the applicable Canadian securities regulatory
authorities.
SOURCE Waverley Pharma Inc.